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Oxaliplatin causes peripheral neuropathy as a major dose-limiting side effect, and the control of this
neuropathy is difﬁcult. This study was designed to investigate whether prophylactic repetitive admin-
istration of 5-HT1A receptor agonists inhibits oxaliplatin-induced mechanical allodynia in mice. Repeti-
tive administration of 5-HT1A receptor agonists (xaliproden and tandospirone) inhibited mechanical
allodynia induced by a single intraperitoneal injection of oxaliplatin. These agonists also inhibited
oxaliplatin-induced mast cell migration, which is involved in the induction of mechanical allodynia.
These results suggest that the prophylactic repetitive administration of 5-HT1A receptor agonists at-
tenuates oxaliplatin-induced mechanical allodynia by inhibiting the cutaneous mast cell migration.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Oxaliplatin, a platinum-based chemotherapeutic agent, is used
for the treatment of colorectal cancer; however, it causes sensory
neuropathy with symptoms including pain and dysesthesia, as
dose-limiting side effects (1). The underlying mechanisms of
oxaliplatin-induced pain and dysesthesia are not completely
understood.
Mast cells are immune cells and are involved in the induction of
pain (2). Oxaliplatin causes mast cell-mediated anaphylactic re-
actions (3). Recently, we demonstrated that a single intraperitoneal
injection of oxaliplatin induced mechanical allodynia together with
an increase of mast cells in the skin (4). We also showed that the
serine proteases from mast cells were involved in the induction of
mechanical allodynia. Furthermore, it was shown that the activa-
tion of capsaicin-sensitive sensory neurons plays an important role
in the mast cell migration induced by oxaliplatin (4). Therefore,
controlling the increase of mast cells is important to inhibit the
exacerbation of oxaliplatin-induced mechanical allodynia.armacology, Graduate School
y of Toyama, 2630 Sugitani,
doh).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).A selective 5-HT1A receptor agonist shows an analgesic effect
(5); also minimizes oxaliplatin-induced peripheral neuropathy in
cancer patients (6). However, the underlying mechanisms of the
inhibitory action of 5-HT1A receptor agonists in the oxaliplatin-
induced peripheral neuropathy are still unclear. As mentioned
earlier, cutaneousmast cells play an important role in the induction
of mechanical allodynia in oxaliplatin-treated mice (4). In this
study, therefore, the effect of 5-HT1A receptor agonists (e.g., xali-
proden and tandospirone) on oxaliplatin-induced mechanical
allodynia and mast cell migration was investigated.
Male C57BL/6NCr mice (6-week-old at the start of the experi-
ment; Japan SLC, Ltd., Hamamatsu) were used in this study. They
were kept under controlled temperature (21e23 C), humidity
(45e65%), and light (12h:12h dark:light cycle). They were given
free access to food and water. The animal experiment procedures
were approved by the Committee for Animal Experiments at the
University of Toyama and were conducted in accordance with the
guidelines of the Japanese Pharmacological Society.
Oxaliplatin (Wako Pure Chemical Industries, Osaka) was dis-
solved in 5% glucose and was injected intraperitoneally. A recom-
mended dose of oxaliplatin is 85 mg/m2 body surface area (7),
which corresponds to 2.4 mg/kg when the body height and weight
are 170 cm and 60 kg, respectively (4); therefore, a 3.0 mg/kg dosenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Fig. 1. The effects of prophylactic repetitive administration of xaliproden (XPD) and
tandospirone (TSP) on oxaliplatin (OXP)-induced mechanical allodynia. On day 0, OXP
(3 mg/kg) or the vehicle (VH1) was administered to the mice by intraperitoneal in-
jection. XPD, TSP or the vehicle (VH2) was orally administered immediately after OXP
injection on day 0 and was administered once daily from the next day after the
behavioral evaluation. Mechanical allodynia was tested by punctate stimulation using
a von Frey ﬁlament (a bending force of 0.69 mN). (A) Mechanical allodynia after a
single injection of OXP or the vehicle (VH1). *P < 0.05 when compared with VH1,
(HolmeSidak test) (VH1, n ¼ 6; OXP, n ¼ 6). The two-way repeated measures ANOVA
demonstrated a signiﬁcant effect of the treatment (F1,10 ¼ 99.941, P < 0.001) and an
T. Andoh et al. / Journal of Pharmacological Sciences 131 (2016) 284e287 285of oxaliplatin was chosen for this study. Xaliproden hydrochloride
(Tocris Bioscience., Ellisville, MO, USA) (4, 8) and tandospirone
(Toronto Research Chem. Inc., Toronto, ON, Canada) (9, 10) were
dissolved in 0.5% sodium carboxymethyl cellulose. Xaliproden and
tandospirone were orally administered immediately after oxali-
platin injection on day 0 and subsequently, once daily after the
behavioral evaluation. The volume for administration was 0.1 ml/
10 g body weight regardless of the administration route.
Mechanical allodynia of the hind pawswas assessed by punctate
stimulation with a von Frey ﬁlament (a bending force of 0.69 mN,
North Coast Medical Inc., Morgan Hill, CA, USA) (4,11). Responses to
the stimuli were scored as follows: 0, no reaction; 1, lifting of the
hind paw; and 2, licking and ﬂinching of the hind paw. Stimulations
were applied to each hind paw three times at intervals of several
seconds, and the average response score served as the allodynia
score (the maximum score was 2).
Toluidine blue staining was performed as reported previously
(4). Brieﬂy, before oxaliplatin injection or on day 3, 5, 7, and 10 after
the injection, the mice were transcardially perfused with
phosphate-buffered saline (PBS) followed by perfusion with 4%
paraformaldehyde. The plantar skin was excised, postﬁxed with 4%
paraformaldehyde for 4 h, and immersed in 30% sucrose solution
for 4 days. The tissue was embedded in Tissue-Tek® O.C.T. com-
pound (Sakura Fineteck Co., Ltd., Tokyo) and was kept at 80 C
until use. The frozen samples were sectioned at 20 mm thickness
with a cryostat (Leica, Wetzlar, Germany). After washing with PBS,
the sections were stainedwith 0.1% toluidine blue and washedwith
tap water. The slides were dehydrated by sequential immersion in
50%, 70%, 80%, and 90% ethanol for 1 min each, followed by 100%
ethanol and xylene immersions for 10 min each. The sections were
mounted with Canada balsam and observed using a light micro-
scope (BX-61, Olympus, Osaka) with a charge-coupled device
camera (DP70, Olympus).
Data are presented as mean ± standard error of mean (S.E.M.).
Statistical signiﬁcance between groups was analyzed using one- or
two-way analysis of variance (ANOVA) or two-way repeated mea-
sures ANOVA followed by a post hoc HolmeSidak test; P < 0.05 was
considered signiﬁcant.
A single intraperitoneal injection of oxaliplatin (3mg/kg) induced
mechanical allodynia in mice. The effect peaked 10 days after the
injection and almost completely subsided by day 20 (Fig. 1A). Pro-
phylactic repetitive oral administration of xaliproden (0.3e3 mg/kg)
(Fig. 1B) and tandospirone (1e3 mg/kg) (Fig. 1C) signiﬁcantly
inhibited the oxaliplatin-induced mechanical allodynia when
compared to the vehicle-administered mice. Xaliproden (3 mg/kg)
(Fig. 1B) and tandospirone (3 mg/kg) (Fig. 1C) completely inhibited
the development of oxaliplatin-induced mechanical allodynia.
A single intraperitoneal injection of oxaliplatin (3 mg/kg)
increased the number of mast cells in the plantar skin
(Supplemental Fig. 1). Mast cells were mainly distributed in the
dermis and subcutaneous tissue (Fig. 2). The number of mast cells
in the plantar skin of mice that received oxaliplatin injection was
signiﬁcantly higher than that in the vehicle-injected mice (Fig. 2).
Prophylactic repetitive oral administration of xaliproden (3 mg/kg)interaction between the treatment and time (F12,120 ¼ 17.982, P < 0.001). (B) The effect
of XPD on OXP-induced mechanical allodynia. *P < 0.05 when compared with
OXP þ VH2, (HolmeSidak test) (OXP þ VH2, n ¼ 5; OXP þ XPD (0.3 mg/kg), n ¼ 5;
OXP þ XPD (1 mg/kg), n ¼ 5; OXP þ XPD (3 mg/kg), n ¼ 6). The two-way repeated
measures ANOVA demonstrated a signiﬁcant effect of the treatment (F3,17 ¼ 85.5,
P < 0.001) and an interaction between the treatment and time (F30,170 ¼ 7.01,
P < 0.001). (C) The effect of TSP on OXP-induced mechanical allodynia. *P < 0.05 when
compared with OXP þ VH2, (HolmeSidak test) (OXP þ VH2, n ¼ 6; OXP þ TSP (1 mg/
kg), n ¼ 6; OXP þ TSP (3 mg/kg), n ¼ 6). The two-way repeated measures ANOVA
demonstrated a signiﬁcant effect of the treatment (F2,15 ¼ 147.05, P < 0.001) and an
interaction between the treatment and time (F20,150 ¼ 10.55, P < 0.001).
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Fig. 2. The effects of prophylactic repetitive administration of xaliproden (XPD) and
tandospirone (TSP) on the increase in the number of cutaneous mast cells in mice
treated with oxaliplatin (OXP). On day 0, OXP (3 mg/kg) or the vehicle (VH1) was
administered to the mice by intraperitoneal injection. XPD (3.0 mg/kg), TSP (3.0 mg/
kg) or the vehicle (VH2) was orally administered immediately after OXP injection on
day 0 and once daily from the next day after the behavioral evaluation. (A) (Upper
panels) Typical examples of toluidine blue staining in the plantar skin of mice. The
arrowhead shows a typical example of mast cell strained with toluidine blue. Scale bar,
100 mm. (Lower panel) The total number of mast cells in the skin samples (4e8 sec-
tions per animal). Area, 0.12 mm2. n ¼ 4 in each group. *P < 0.05 (HolmeSidak test). (B)
The total number of mast cells in the skin samples (5 sections per animal). Area,
0.12 mm2. n ¼ 6 in each group. *P < 0.05 (HolmeSidak test).
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ted the increase in the number of cutaneous mast cells in
oxaliplatin-treated mice.
In a previous report, we have shown that a single oral admin-
istration of xaliproden does not inhibit oxaliplatin-inducedmechanical allodynia (11). Therefore, it can be suggested that
xaliproden does not have an acute effect against oxaliplatin-
induced mechanical allodynia. However, in this study, the pro-
phylactic repetitive administration of xaliproden and tandospirone
inhibited the increase in the number of cutaneous mast cells and
inhibition of mechanical allodynia in oxaliplatin-treated mice.
These ﬁndings suggest that the inhibition of mast cell migration by
5-HT1A receptor agonists (xaliproden and tandospirone) is involved
in the inhibition of oxaliplatin-induced mechanical allodynia.
The mechanisms underlying oxaliplatin-induced mast cell
migration in the skin are still unknown. The activation of capsaicin-
sensitive sensory neurons is involved in oxaliplatin-induced mast
cell migration (4). In addition, prophylactic administration of
aprepitant, which is a selective neurokinin-1 receptor (substance P
receptor) antagonist, attenuates the exacerbation of oxaliplatin-
induced mechanical allodynia and cutaneous mast cell migration
(Supplemental Fig. 2). Substance P is a neuropeptide released from
the sensory neurons and induces the expression of mast cell
migration-related factors (such as interleukin-8 and tumor necrosis
factor) (12) in keratinocytes (13). Capsaicin treatment reduces the
expression of substance P (14), which is released through the in-
crease of intracellular Ca2þ (15). Oxaliplatin induces an increase in
the intracellular Ca2þ concentration in primary sensory neurons
(S1). Therefore, as one possible mechanism, substance P released
from capsaicin-sensitive sensory neurons may be involved in the
oxaliplatin-induced mast cell migration in the skin. In the present
study, repetitive administration of 5-HT1A receptor agonists
inhibited the oxaliplatin-induced mast cell migration. In addition,
the oral administration of xaliproden inhibited the increase in pe-
ripheral nerve activity induced by mechanical stimulation (von
Frey ﬁlament, bending force of 0.69 mN) in oxaliplatin-treatedmice
(11). Therefore, it is suggested that 5-HT1A receptor agonists
including tandospirone have a peripheral action. 5-HT1A receptors
are expressed in capsaicin-sensitive primary afferents (S2). The 5-
HT1A receptor agonists inhibit the Ca2þ channel current, which is
related to the release of substance P (S3). Consequently, 5-HT1A
receptor agonists may decrease the oxaliplatin-induced mast cell
migration by inhibiting the release of substance P from capsaicin-
sensitive sensory neurons.
The deﬁciency of capsaicin-sensitive C-ﬁber sensory neurons
attenuates oxaliplatin-induced mechanical allodynia and mast cell
migration (4). Mechanical allodynia is primarily mediated by A-ﬁ-
ber, but not C-ﬁber, sensory neurons. The C-ﬁbermay be involved in
the activation and migration of mast cells, whereas the A-ﬁber
activated by themast cell mediators (e.g., tryptase) may be involved
in the induction of mechanical allodynia. Since the 5-HT1A re-
ceptors are mainly expressed in capsaicin-sensitive C-ﬁber (S2), the
regulation of C-ﬁber by the activation of 5-HT1A receptor may lead
to the inhibition of mechanical allodynia due to the inhibition of
mast cell migration.
In conclusion, these results suggest that 5-HT1A receptor ago-
nists (e.g., xaliproden and tandospirone) inhibit neuropathic allo-
dynia caused by oxaliplatin by inhibiting the mast cell migration in
the skin. The underlying mechanisms of the regulation of
oxaliplatin-induced mast cell migration by 5-HT1A receptor ago-
nists will be investigated in future studies.
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